发布求助

文献互助智能选刊最新文献

Japanese Journal of Cancer and Chemotherapy最新文献

筛选

英文中文

[Investigation of the Changes in Blood Cell Components following the Administration of Pegfilgrastim in Neo-Adjuvant and Adjuvant FEC Chemotherapy for Breast Cancer]. [乳腺癌新辅助和辅助 FEC 化疗中使用 Pegfilgrastim 后血细胞成分变化的研究]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-09-01

Maimi Asano, Hisanori Shimizu, Takashi Yokokawa, Wataru Suzuki, Kazuyoshi Kawakami, Kazuo Kobayashi, Takahito Sugisaki, Takeshi Aoyama, Sari Shikibu, Takuya Tomomatsu, Ippei Fukada, Toshimi Takano, Masakazu Yamaguchi

{"title":"[Investigation of the Changes in Blood Cell Components following the Administration of Pegfilgrastim in Neo-Adjuvant and Adjuvant FEC Chemotherapy for Breast Cancer].","authors":"Maimi Asano, Hisanori Shimizu, Takashi Yokokawa, Wataru Suzuki, Kazuyoshi Kawakami, Kazuo Kobayashi, Takahito Sugisaki, Takeshi Aoyama, Sari Shikibu, Takuya Tomomatsu, Ippei Fukada, Toshimi Takano, Masakazu Yamaguchi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Perioperative fluorouracil, epirubicin and cyclophosphamide(FEC)therapy is a standard treatment for breast cancer. However, more than 20% of patients with breast cancer who undergo FEC therapy experience febrile neutropenia(FN), for which pegfilgrastim is commonly recommended as primary prophylaxis. Although the efficacy and safety of pegfilgrastim were verified at the time of drug approval, there are still no reports on its long-term safety. In this study, we assessed the long-term safety of pegfilgrastim and changes in blood cell components, further assessing the incidence of FN. There were no significant differences in the leukocyte count, neutrophil count, lymphocyte count, hemoglobin concentration, or platelet count with or without the use of pegfilgrastim at 1 year. No long-term effects of pegfilgrastim on blood cell components were observed. The incidence of FN was 6.5% with pegfilgrastim administration and 22.8% without pegfilgrastim administration(p=0.020). Primary prophylaxis with pegfilgrastim can reduce the incidence of FN and can be safely used for 1 year after initial administration in patients with breast cancer undergoing chemotherapy.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 9","pages":"913-918"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pathological Complete Response to Neoadjuvant Chemotherapy for Abscess-Forming Rectal Cancer-A Case Report]. [脓肿型直肠癌对新辅助化疗的病理完全反应--病例报告]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Kenji Namiki, Yoshinori Iwata, Shuji Komori, Chihiro Tanaka, Narutoshi Nagao, Masahiko Kawai

引用次数: 0

[Persistent Effects of Mogamulizumab on Peripheral Blood Lesions after Treatment Completion in a Patient with Refractory Sézary Syndrome-A Case Report]. [难治性塞扎瑞综合征患者治疗结束后莫干单抗对外周血病变的持续作用--病例报告］

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Masahiro Manabe, Hideki Endo, Naoyuki Inano, Yuuji Hagiwara, Satoru Nanno, Ki-Ryang Koh

引用次数: 0

[A Case of Radical Hepatectomy in a Patient with Recurrent Liver Metastasis of Gallbladder Cancer after Successful Chemotherapy with GC+Durvalumab]. [胆囊癌复发肝转移患者成功接受 GC+Durvalumab 化疗后行根治性肝切除术的病例].

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Taiichiro Miyake, Takeshi Urade, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Keisuke Arai, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

{"title":"[A Case of Radical Hepatectomy in a Patient with Recurrent Liver Metastasis of Gallbladder Cancer after Successful Chemotherapy with GC+Durvalumab].","authors":"Taiichiro Miyake, Takeshi Urade, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Keisuke Arai, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 49-year-old man underwent an open cholecystectomy for advanced gallbladder cancer in 2021. Three months after surgery, the patient underwent an additional resection, which showed no malignant findings, but 12 months after surgery, contrast-enhanced CT and MRI showed a new mass lesion in segment 8 of the liver, and the patient was diagnosed with postoperative hepatic metastatic recurrence of gallbladder cancer. After referral to our institution, he received 1 course of gemcitabine+cisplatin(GC)therapy and 8 courses of gemcitabine+cisplatin+durvalumab(GCD)therapy. Contrast- enhanced CT and MRI showed that the metastases had shrunk, and PET scan showed no FDG accumulation. Two months after completion of chemotherapy, there was no evidence of metastatic enlargement and new metastasis including distant metastasis, and the patient was referred to our department. Since curative resection was expected, a laparoscopic partial hepatectomy of segment 8 of the liver was performed. Pathological diagnosis revealed no residual tumor. If the metastases could be well controlled by systemic chemotherapy, hepatectomy for hepatic metastases of biliary tract cancer could be a treatment option.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 8","pages":"843-845"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ⅲ. Latest Topics of Lung Neuroendocrine Neoplasms]. [肺神经内分泌肿瘤的最新课题]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Katsuhiko Naoki

引用次数: 0

[Patient Questionnaire Survey of"As-Needed"Medications to Relieve Side Effects and Anxiety for Breast Cancer Chemotherapy]. [关于缓解乳腺癌化疗副作用和焦虑的 "按需 "药物的患者问卷调查]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Tatsuki Ikeda, Satoru Nihei, Kazuki Saito, Sachiko Shibuya, Kazushige Ishida, Kenzo Kudo

引用次数: 0

[A Case of Appendiceal Mucinous Carcinoma with Bladder Invasion Developed from Abscess-Forming Appendicitis, Which Was Curatively Resected after Chemotherapy]. [一例由脓肿形成性阑尾炎发展而来的阑尾粘液腺癌伴膀胱侵犯，化疗后治愈切除】。］

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Yuki Yoshihara, Takuji Kagiya, Yoshiyuki Sakamoto, Hajime Morohashi, Takuya Miura, Kazuki Yokoyama, Kenichi Hakamada

{"title":"[A Case of Appendiceal Mucinous Carcinoma with Bladder Invasion Developed from Abscess-Forming Appendicitis, Which Was Curatively Resected after Chemotherapy].","authors":"Yuki Yoshihara, Takuji Kagiya, Yoshiyuki Sakamoto, Hajime Morohashi, Takuya Miura, Kazuki Yokoyama, Kenichi Hakamada","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a 35-year-old man who saw his first doctor with the chief complaint of painful urination. A contrast- enhanced CT scan of the abdomen revealed a diagnosis of abscess-forming appendicitis with inflammatory spread to the bladder, and conservative treatment was decided. Since antibiotic treatment failed to reduce the size of the abscess, he underwent surgery. The bladder wall was highly inflamed, only appendectomy was performed. Pathology revealed appendiceal mucinous carcinoma invading the bladder, so he was referred to our department. Because a total cystectomy was required for curative resection and there was concern about seeding associated with the initial surgery, he was judged to be unresectable, and received chemotherapy. After 6 courses of CAPOX+bevacizumab therapy, he was able to have a bladder- sparing curative resection because of the absence of distant metastasis and shrinkage of the tumor. He remains stable without recurrence 6 months after surgery. We herein report, with some discussion of the literature, this case of bladder-invading appendiceal mucinous carcinoma arising from abscess-forming appendicitis, for which a curative resection was possible after chemotherapy.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 8","pages":"849-851"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Ⅱ. Updates on Therapeutic Strategies for Malignant Mediastinal Tumors]. [恶性纵隔肿瘤的最新治疗策略]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Masanori Shimomura, Satoru Okada, Tatsuo Furuya, Masayoshi Inoue

引用次数: 0

[Evaluation of Health Economics in Oncology Drug Therapy]. [肿瘤药物治疗中的卫生经济学评估]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Yasushi Goto

{"title":"[Evaluation of Health Economics in Oncology Drug Therapy].","authors":"Yasushi Goto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cancer treatment has made remarkable progress in recent years, particularly in the field of drug therapy. However, the high-cost of new drugs has led to active discussions about cost-effectiveness in cancer treatment. This article examines the pharmacoeconomics of drug therapy in cancer treatment from both macro and micro perspectives. From a macro perspective, Japan's drug pricing system determines prices based on the presence or absence of similar drugs. The system aims to balance the incentives for developing innovative new drugs with the sustainability of healthcare costs. The increasing share of drug costs in overall healthcare expenditure, especially for anticancer drugs, poses a significant challenge. From a micro perspective, hospitals face challenges in managing their revenue structure due to the low profit margins on anticancer drugs and the complex diagnosis-related group(DPC)classification system. The use of expensive anticancer drugs, such as immune checkpoint inhibitors, increases the drug cost burden on hospitals. While the high-cost medical care benefit system sets an upper limit on patient out-of-pocket expenses, the increasing use of high-priced drugs remains a concern for both patients and healthcare providers. Balancing patient access to innovative treatments with the sustainability of healthcare costs is a critical issue in cancer drug therapy. Addressing this challenge requires a comprehensive approach that considers both macro and micro perspectives.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 8","pages":"791-794"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Health Economic Evaluation of Surgical Treatment for Cancer]. [癌症外科治疗的卫生经济评估]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2024-08-01

Minoru Esaki, Ataru Igarashi, Shunsuke Tsukamoto, Shunsuke Sugawara, Masau Sekiguchi, Atsuro Fujinaga

{"title":"[Health Economic Evaluation of Surgical Treatment for Cancer].","authors":"Minoru Esaki, Ataru Igarashi, Shunsuke Tsukamoto, Shunsuke Sugawara, Masau Sekiguchi, Atsuro Fujinaga","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Conducting\"health economic evaluation\"is one of the most important issues for the efficient allocation of healthcare costs. Although the Central Social Insurance Medical Council in Japan(Chuikyo)introduced a cost-effectiveness evaluation system for drugs and medical devices in 2019, there are no reports of the system being officially utilized for medical procedures, including surgical treatments. Because it is often required to provide the best possible treatment to save lives, cancer care is an area where it is difficult to adapt\"health economic evaluation\". In addition, surgical treatment is more invasive than medical checkups or drug therapy, and complications and hospitalization costs vary widely from case to case, so the cooperation of the medical affairs department is essential in examining medical costs for health economic evaluation. Although QOL surveys are important for the evaluation of invasiveness, there are almost no large-scale studies that reflect the actual conditions of treatment, and none for Japanese and for patients undergoing cancer treatment. It is essential to conduct QOL surveys for future health economic evaluation. We will explain\"health economic evaluation\"of surgical treatment for cancer, using as examples the results of medical technology evaluation of surgical techniques that we have reviewed. In considering the\"health economic evaluation\"of surgical treatment for cancer, the medical cost and QOL surveys were considered to be particularly important. We look forward to future research.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"51 8","pages":"795-800"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

10

联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1

京公网安备 11010802042870号

Book学术文献互助

Book学术文献互助群
群号：481959085

Book学术官方微信